As 2019 begins, Koji Hasegawa will pass the ISCP presidency to Augusto Gallino, who will take over as President in 2019. Prof Gallino is also the co-president of the Organising Committee for the 24th ISCP Annual Scientific Meeting along with Juan Carlos Kaski.
If you are considering attending the 24th Annual Scientific Meeting of the ISCP in Lugano, Switzerland on the 9th-10th of May 2019, information is available on the conference website: www.iscp2019.com. This includes the preliminary programme and information on abstract submission. World expert speakers in the field of cardiovascular pharmacotherapy include Eugene Braunwald, Peter Libby, Thomas Luescher and Salim Yusuf, who will present the Henry N Neufeld Lecture.
Please forward any news or information on upcoming conferences or meetings that you would like included in the March 2019 Newsletter to me at firstname.lastname@example.org by 22 February 2019.
Wishing everyone all the best for 2019
Editors: John McNeil & Lisa Demos
Welcome to the Winter issue of the ISCP Newsletter. Articles in this issue include reports from the Cardiovascular Clinical Trialist (CVCT) Forum in Washington DC, the 2nd ISCP Korea Chapter in Seoul, and the World Congress of Cardiology (WCC) in Dubai. Members of the ISCP significantly contributed to the great success of these meetings.
We come to the end of another year and look back at some of the ISCP events. Our scientific meeting in Kyoto in May was very successful and it was a great privilege to be able to share our knowledge of cardiovascular pharmacotherapy and that of the other speakers with the many delegates. Our 2019 Scientific Meeting will be in Lugano, Switzerland and we hope that most of you will be able to attend. Looking forward to seeing everyone in Lugano next May!
The year also saw the further expansion of the ISCP website. We do hope that you are finding the new sections both interesting and useful.
Finally and most importantly, we wish you and your families, health, friendship and prosperity for the coming year.
Prof Koji Hasegawa,
Chair, 23rd Annual Scientific Meeting of ISCP
The Scientific Meeting is organized in collaboration with the Working Group on Cardiovascular Pharmacotherapy (European Society of Cardiology), the Swiss Society of Cardiology (SSC) and the Swiss Atherosclerosis Association, the French Society of Cardiology and the Cardiovascular Clinical Trials Forum (CVCT).
The ISCP wishes to encourage the participation of young researchers, MD and PhD students – three Young Investigator Awards will be awarded to the three best posters in this category. There will be ample opportunity during the meeting for the attendees to meet colleagues and experts in different fields of cardiovascular medicine.
Authors are invited to submit abstracts for consideration as oral or poster presentations. The deadline for the submission of an abstract is 1 March 2019. The abstracts will be published online in the ISCP official journal – European Cardiology Review – and on the ISCP website.
Early registration rates are available until 9 March 2019. Discounted registration rates are available to students, doctors in training and nurses.
More information is available on the conference website: www.iscp2019.com.
New ISCP Governors:
15th Global Cardiovascular Clinical Trialists (CVCT) Forum, 29th November – 1st December 2018:
This included the CVCT-ISCP joint session entitled “Globalization of Cardiovascular Clinical Trials Opportunities, Challenges and Unmet Needs” with the president, Koji Hasegawa, and the past president, Felipe Martinez, serving as chairs. The objective of the session was to gain insight in local/regional conditions with the aim of maximizing quality and efficiently of cardiovascular trials and improve generalizability of the results of these trials.
Faiez Zannad (Nancy, France), an organizer of the forum, explained the situation of clinical research in the African and Middle East region. Understanding trial standards and paradigms by medical workers has much improved. Thus, he stressed that the investment to this region by industries is attractive. Felipe Martinez described the clinical trial situation in Latin America, and he spoke on Chagas disease, which causes severe heart failure and is prevalent in this region. Although Chagas disease is decreasing in Latin America, it is spreading across the world. From the regulatory viewpoint, Robert Temple (FDA, USA) described the basic standard regulations to incorporate international trial data into the clinical settings in USA. John Jarcho (Deputy Editor, NEJM) and Stuart Spence (Senior Executive Editor, The Lancet) stressed the importance of ethical issues in clinical trials. The session also included presentations on the Industry, Regulatory and Patient viewpoint.
The joint session was a great success with a lot of active discussion during the Moderated Multi-Stakeholder Expert Panel Debate with the Audience. In particular, there were many comments and questions from patients, the press, and scientists.
World Congress of Cardiology in Dubai, 5th – 8th of December 2018:
Several ISCP members actively participated in the recent World Congress of Cardiology as speakers or session chairs including the ISCP President and Past President.
In the Cardiogenic Stroke session, which included speakers from Singapore, Italy and the USA, Antoni Martínez-Rubio (Spain), spoke on the Differences between NOACS for the prevention of stroke in atrial fibrillation.
A session chaired by Koji Hasegawa (Japan) and Ali Oto (Turkey) titled Real world prevention of stroke in atrial fibrillation: how guidelines are applied, included talks from both Antoni Martínez-Rubio and Ali Oto. These presentations were followed by an interesting discussion with the audience regarding the indications of anticoagulation, different scales of embolic and bleeding risk, antithrombotic drug differences and clinical experience in different scenarios and ethnicities.
The session on Genetics and Global CVD Burden included a presentation by Koji Hasegawa on Pharmacogenetics and Cardiovascular Disease. Whilst in the session Management Strategies in Women, Ali Otto spoke on Gender Differences in the Management of Atrial Fibrillation. The session on Novel Therapies to Reduce Cardiovascular Risk, included a presentation by Alberto Lorenzatti on the New Frontiers in the Management of Lipids speaking about PCSK9 inhibition, CTEP Inhibitors and other new developments.
The topic of “Lipids and Prevention of Acute Coronary Syndromes” was presented in an interesting and interactive session. Junji Kobayashi (Japan) spoke on “Residual Risk of Coronary Atherosclerosis” whilst Alberto Lorenzatti (Argentina) spoke on “LDL cholesterol: how low we can go.” Alberto Lorenzatti’s presentation took into consideration the current utilization of statins and the new evidence from recent studies with non-statin interventions.
Ali Oto also gave several other presentations including Oral Anticoagulation in the Octogenerian: Is it safe?; Is There a Need for Anti-Arrhythmic Drugs Following AF Ablation?; When to Refer Patients for AF Ablation.
The 2nd meeting of ISCP Korea Chapter (K-ISCP) – 30th of November 2018:
Masayuki Yoshida, ISCP Governor for Japan: I am happy to report on the 2nd ISCP Korea Chapter (K-ISCP) in Seoul, which included the first Korea-Japan ISCP joint session. The meeting was organized by Prof Sang-Hong Baek, the K-ISCP Governor. Sessions included: Cardiovascular Effect of Anti-Diabetic Drugs; Maximizing Drug Effect in Coronary Artery Disease (the Korean-Japan Chapter ISCP Joint session); and Emerging Therapy in Cardiovascular Disease. Speakers for the Joint Korean-Japan session included Prof Koichi Kaikita and Prof Masayuki Yoshida from Japan and Sang-Hong Baek from Korea.
The meeting was well organized and included a special lecture by Prof Jin Tae Oh. Each session was chaired by two distinguished scientists from South Korea. Prof Baek asked three to four faculty scientists to join each session as panelists to ask questions or give comments. There were many comments and questions from the more than 100 delegates from the fields of cardiology, endocrinology, and pharmacology.
I really appreciate Prof Baek’s work and promotion of K-ISCP and the support from his colleagues and the Korean industries. I am fully convinced that K-ISCP is going exceedingly smoothly and would like to congratulate Prof Baek for the success of the 2nd K-ISCP meeting. Prof Baek has planned a two-day meeting for the 3rd K-ISCP on 1st of June 2019.
WHF Board and President Elect: The WHF Board of Directors 2019-2020 was recently announced along with the new President-Elect Fausto Pinto.
World Congress of Cardiology & Cardiovascular Health 2019: The Congress now takes place every year. In 2019 it will be held in Paris, in partnership with the European Society of Cardiology (ESC).
40 years of the World Heart Federation: Watch the 40th Anniversary video that features President Prof David Wood, President-Elect Prof Karen Sliwa, and Past Presidents Prof Antonio Bayés de Luna, Prof Valentin Fuster, Prof Mario Maranhao, Prof Pekka Puska, Prof Sidney Smith, Prof K. Srinath Reddy and Prof Salim Yusuf.
The WHF Roadmaps: These have become a cornerstone for highlighting priority disease areas in cardiovascular disease. The intended purpose of these documents is to establish frameworks that examine a specific disease area, its ideal patient-care pathway and the roadblocks and potential solutions that may be applicable and acceptable in different contexts; their overall purpose, aligned with WHF priority to reduce the burden of cardiovascular disease.
A Roadmap is a framework designed to help identify challenges (roadblocks) and suggest potential solutions on the way to a relative reduction of premature mortality caused by cardiovascular disease of 25% by 2025 (25 by 25). In 2019, the WHF will be launching 3 new Roadmaps:
- WHF Roadmap on CVD & Diabetes, co-chaired by Prof Nam Cho (International Diabetes Federation) and Prof Laurence Sperling (World Heart Federation)
- WHF Roadmap on Heart Failure, chaired by Prof Karen Sliwa-Hahnle (World Heart Federation)
- WHF-IASC Roadmap on Chagas Disease, in partnership with the Inter American Society of Cardiology
Tackling Air Pollution to Prevent NCDs: The World Heart Federation participated in the First WHO Conference on Air Pollution and Health, where WHF advocated for increased action on air pollution and made important commitments in the areas of research, awareness and advocacy.
New CoP on NCDs and Commercial Determinants of Health: The WHO GCM/NCD, alongside the Global Health Centre at Graduate Institute of International and Development Studies and CPC Analytics, launched a new Community of Practice (CoP) on noncommunicable diseases (NCDs) and commercial determinants of health (CDoH). A webinar titled “The commercial determinants of health – towards a productive debate” launched the new CoP on 20 November 2018.
White Paper for Circulatory Health: Driving Sustainable Action for Circulatory Health: The White Paper was launched by the Global Coalition for Circulatory Health. It is aimed at national and international policymakers, is a solution-oriented document, based on the Political Declaration of the High-level Meeting, which draws on success stories and patient testimonies to present feasible actions in education and training, universal health coverage, financing, infrastructure, and access to medicines and technologies to advance circulatory health.
The Current Cardiovascular Therapy Series is created with the support of the ISCP. The books provide both an in-depth view of the science and pharmacology behind these drugs and a practical guide to their usage. Each volume is designed to be between 120 and 250 pages, containing practical illustrations and designed to improve understanding and practical usage of cardiovascular drugs in specific clinical areas.
The series currently includes 9 books: Antiplatelet and Anticoagulation Therapy; Pharmacological Treatment of Acute Coronary Syndromes; Atrial Fibrillation Therapy; Cardiac Drugs in Pregnancy; Pharmacotherapy in Aortic Disease; Pharmacologic Trends of Heart Failure; Pharmacological Treatment of Chronic Stable Angina Pectoris; ACEi and ARBS in Hypertension and Heart Failure; Treatment of Pulmonary Hypertension.
The books are available as e-books or in soft cover at a discounted rate for ISCP members.
The European Cardiology Review is a peer-reviewed bi-annual journal comprising review articles, editorials and case reports. The journal is led by Editor-in-Chief Juan Carlos Kaski, supported by Associate Editors, and underpinned by an editorial board of world-renowned physicians.
Publications in volume 13, Issue 2 Winter 2018. A strong Pharmacology section comprises contributions on a range of topics, including the East Asian paradox – Asians who have had percutaneous coronary intervention are at a lower risk of ischaemic events than Caucasians even though they have a higher platelet reactivity. Koji Hasegawa, past ISCP President, presents a selection of best posters from the society’s 23rd Annual Scientific Meeting Kyoto.
Publications and online first articles are accessible via the website. The ECR is a free on-line review accessible via the ECR website. Article PDFs can be accessed via login or by registering. ECR is now indexed on PubMed Central and PubMed and articles are published in full online on PubMed Central.
16 – 18 March, 2019 New Orleans, USA
ISCP 23rd Annual Scientific Meeting
9 – 10 May 2019
XXVII Congreso InterAmericano De Cardiología 2019
15 – 18 May, 2019
To unsubscribe to the Newsletters please notify: Begoña Lugg the ISCP Administration Officer at email@example.com or fax: +44 (0)20 8725 3416